TMEM37, transmembrane protein 37, 140738

N. diseases: 12; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.300 Biomarker group CTD_human In primary mammary carcinomas, five (Angptl4, Coro1a, RGD1304982, Tmem37 and Ndn) of the 29 genes were methylated in one or more of 25 samples. 21489049 2011
CUI: C0024667
Disease: Animal Mammary Neoplasms
Animal Mammary Neoplasms 		0.300 Biomarker phenotype CTD_human Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 21489049 2011
CUI: C0205696
Disease: Anaplastic carcinoma
Anaplastic carcinoma 		0.300 Biomarker disease CTD_human Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 21489049 2011
CUI: C0205697
Disease: Carcinoma, Spindle-Cell
Carcinoma, Spindle-Cell 		0.300 Biomarker disease CTD_human Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 21489049 2011
CUI: C0205698
Disease: Undifferentiated carcinoma
Undifferentiated carcinoma 		0.300 Biomarker disease CTD_human Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 21489049 2011
CUI: C0205699
Disease: Carcinomatosis
Carcinomatosis 		0.300 Biomarker phenotype CTD_human Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 21489049 2011
CUI: C1257925
Disease: Mammary Carcinoma, Animal
Mammary Carcinoma, Animal 		0.300 Biomarker disease CTD_human Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 21489049 2011
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.020 Biomarker phenotype BEFREE We have also shown that cross-presentation of PR1 by solid tumors renders them susceptible to killing by PR1-targeting immunotherapies. 29661776 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.020 GeneticVariation phenotype BEFREE In patients with detected hotspot TP53 mutant advanced solid tumors (n = 11), the treatment led to a 45% rate of SD ≥6 months/PR (1 PR and 3 SD ≥6 months), median PFS of 3.5 months, and median OS of 12.7 months, compared favorably with the results for patients with undetected hotspot TP53 mutations (n = 25): 16% (1 PR and 3 SD ≥6 months, P = 0.096), 2.0 months (P = 0.042), and 7.4 months (P = 0.1), respectively. 25669829 2015
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.010 Biomarker disease BEFREE The tumoral expression of PRTN3 reinforces the therapeutic potential of PR1-targeting immunotherapy in pancreatic cancer. 30880498 2019
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.010 Biomarker disease BEFREE The tumoral expression of PRTN3 reinforces the therapeutic potential of PR1-targeting immunotherapy in pancreatic cancer. 30880498 2019
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.010 Biomarker disease BEFREE ULBP2 might be a potential novel OS prognostic biomarker in CC, while GRP and TMEM37 could be served as the independent DFS prognostic genes in CC. 29653552 2018
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.010 Biomarker disease BEFREE ULBP2 might be a potential novel OS prognostic biomarker in CC, while GRP and TMEM37 could be served as the independent DFS prognostic genes in CC. 29653552 2018